| __timestamp | ACADIA Pharmaceuticals Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 1860000 |
| Thursday, January 1, 2015 | 90804000 | 2963000 |
| Friday, January 1, 2016 | 186456000 | 6961000 |
| Sunday, January 1, 2017 | 255062000 | 11779000 |
| Monday, January 1, 2018 | 265758000 | 13697000 |
| Tuesday, January 1, 2019 | 325638000 | 15749000 |
| Wednesday, January 1, 2020 | 388661000 | 18638000 |
| Friday, January 1, 2021 | 396028000 | 27196000 |
| Saturday, January 1, 2022 | 369090000 | 31739000 |
| Sunday, January 1, 2023 | 402466000 | 33491000 |
Infusing magic into the data realm
In the competitive world of biotechnology, effective cost management is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of ACADIA Pharmaceuticals Inc. and Protagonist Therapeutics, Inc. over the past decade.
From 2014 to 2023, ACADIA Pharmaceuticals Inc. has seen a staggering 1,130% increase in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Protagonist Therapeutics, Inc. has experienced a more modest 1,700% rise, indicating a steady yet strategic growth approach.
The data suggests that while ACADIA is investing heavily in scaling operations, Protagonist is cautiously expanding its administrative footprint. Understanding these trends can provide investors with insights into each company's strategic priorities and potential future performance.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Protagonist Therapeutics, Inc.
AbbVie Inc. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs ACADIA Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs MannKind Corporation Trends and Insights